Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Cash (2020 - 2026)

Immuneering's Change in Cash history spans 7 years, with the latest figure at -$81.3 million for Q1 2026.

  • On a quarterly basis, Change in Cash fell 29045.69% to -$81.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $11.5 million, a 137.66% increase, with the full-year FY2025 number at $92.5 million, up 497.66% from a year prior.
  • Change in Cash came in at -$81.3 million for Q1 2026, up from -$98.9 million in the prior quarter.
  • The five-year high for Change in Cash was $201.2 million in Q3 2025, with the low at -$98.9 million in Q4 2025.
  • Historically, Change in Cash has averaged -$1.6 million across 5 years, with a median of -$6.6 million in 2024.
  • Biggest five-year swings in Change in Cash: soared 1485.45% in 2025 and later tumbled 29045.69% in 2026.
  • Year by year, Change in Cash stood at -$3.8 million in 2022, then crashed by 128.37% to -$8.6 million in 2023, then dropped by 4.94% to -$9.1 million in 2024, then crashed by 991.71% to -$98.9 million in 2025, then rose by 17.79% to -$81.3 million in 2026.
  • Business Quant data shows Change in Cash for IMRX at -$81.3 million in Q1 2026, -$98.9 million in Q4 2025, and $201.2 million in Q3 2025.